Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy

被引:59
|
作者
Gallafent, JH
Buskin, SE
De Turk, PB
Aboulafia, DM
机构
[1] Univ Washington, Sch Med, Virginia Mason Med Ctr, Seattle, WA 98111 USA
[2] Virginia Mason Med Ctr, Div Hematol Oncol, Seattle, WA 98101 USA
[3] Virginia Mason Med Ctr, Dept Epidemiol, Seattle, WA 98101 USA
[4] Virginia Mason Med Ctr, Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol Program, Seattle, WA 98101 USA
关键词
D O I
10.1200/JCO.2005.04.156
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Since the advent of highly active antiretroviral therapy (HAART), the incidence of Kaposi's sarcoma (KS) among AIDS patients has declined both nationwide and in King County, Washington. We sought to compare clinical parameters of patients diagnosed with KS in the pre-HAART (1990 to 1996) and HAART (1997 to 2002) eras. Methods We used patient data abstracted from the Adult/Adolescent Spectrum of HIV-Related Diseases study of Public Health-Seattle and King County. Results Patients diagnosed with KS in the HAART era (n = 40) were significantly more likely (P<.05) than pre-HAART-era KS patients (n = 366) to be diagnosed with alcohol problems (43% v 18%), noninjection drug use (45% v 18%), injection drug use (25% v 10%), psychosis (25% v 13%), and hypertension (13% v 2%). Although median CD4(+) count and HIV-1 viral load at the time of KS diagnosis were not significantly different between the two groups, significantly fewer (P <.01) HAART-era KS patients developed opportunistic illnesses (Ols) during their follow-up. The risk of dying among KS patients diagnosed in the HAART era is significantly lower (P <.01) than for KS patients diagnosed in the pre-HAART era (hazard ratio, 0.24). Conclusion Although HAART-era KS patients in King County were as likely to have a depleted CD4(+) cell count and high HIV-1 viral loads at the time of KS diagnosis as pre-HAART KS patients, they survived longer and fewer of them were diagnosed with other Ols. They also had an increased prevalence of substance abuse and mental illness, contributing to a dynamic and changing KS clinical profile.
引用
收藏
页码:1253 / 1260
页数:8
相关论文
共 50 条
  • [1] Profile of patients with Kaposi's sarcoma (KS) in the era of highly active antiretroviral therapy (HAART).
    Gallafent, JH
    Buskin, S
    De Turk, P
    Aboulafia, DM
    [J]. BLOOD, 2003, 102 (11) : 280A - 280A
  • [2] Clinical profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy.
    Gallafent, JH
    Buskin, S
    De Turk, R
    Aboulafia, DM
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S157 - S157
  • [3] Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy
    Palmieri, C.
    Dhillon, T.
    Thirlwell, C.
    Newsom-Davis, T.
    Young, A-M
    Nelson, M.
    Gazzard, B. G.
    Bower, M.
    [J]. HIV MEDICINE, 2006, 7 (05) : 291 - 293
  • [4] Treatment of Kaposi sarcoma in the highly active antiretroviral therapy era
    Dupin, N.
    Del Giudice, P.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (03) : 418 - 420
  • [5] Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era
    El Amari, Emmanuelle Boffi
    Toutous-Trellu, Laurence
    Gayet-Ageron, Angele
    Baumann, Michele
    Cathomas, Gieri
    Steffan, Ingrid
    Erb, Peter
    Mueller, Nicolas J.
    Furrer, Hansjakob
    Cavassini, Matthias
    Vernazza, Pietro
    Hirsch, Hans H.
    Bernasconi, Enos
    Hirschel, Bernard
    [J]. AIDS, 2008, 22 (09) : 1019 - 1028
  • [6] Kaposi's sarcoma associated with highly active antiretroviral therapy
    Crane, HM
    Deubner, H
    Huang, JC
    Swanson, PE
    Harrington, RD
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2005, 16 (08) : 583 - 583
  • [7] A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy
    Stebbing, J
    Sanitt, A
    Nelson, M
    Powles, T
    Gazzard, B
    Bower, M
    [J]. LANCET, 2006, 367 (9521): : 1495 - 1502
  • [8] Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection
    Loke, W. C.
    Spittle, M. F.
    Mitchell, S.
    Kulasegaram, R.
    [J]. INTERNATIONAL JOURNAL OF STD & AIDS, 2006, 17 (08) : 565 - 566
  • [9] Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma
    Tavio, M
    Nasti, G
    Spina, M
    Errante, D
    Vaccher, E
    Tirelli, U
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (08) : 923 - 923
  • [10] Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma
    Martín-Carbonero, L
    Barrios, A
    Saballs, P
    Sirera, G
    Santos, J
    Palacios, R
    Valencia, ME
    Alegre, M
    Podzamczer, D
    González-Lahoz, J
    [J]. AIDS, 2004, 18 (12) : 1737 - 1740